Synergistic bacterial compositions and methods of production and use thereof
Inventors
Henn, Matthew R. • von Maltzahn, Geoffrey • D'Onofrio, Anthony Mario • Litcofsky, Kevin Daniel • Berry, David A. • Cook, David N. • Afeyan, Noubar B. • Aunins, John Grant
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Core Innovation
The disclosure provides purified bacterial consortia designed to treat or prevent an occurrence or recurrence of Clostridium difficile infection in a human subject. The therapeutic composition comprises a first purified bacterial population with a 16S rDNA sequence at least about 97% identical to a reference Collinsella aerofaciens operational taxonomic unit, and a second purified bacterial population with a sequence at least about 97% identical to a reference bacterium of the family Clostridiaceae listed in Table 1.
The two purified bacterial populations form a synergistic combination that is cytotoxic or cytostatic to a pathogenic bacterium and exerts an inhibitory effect in the gastrointestinal tract. Administration of an effective amount ensures that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over time. The described compositions also encompass spore-forming formulations as well as oral or medical-food dosage forms.
Claims Coverage
The claims identify one independent claim comprising four inventive features covering the treatment or prevention of Clostridium difficile infection using two specified purified bacterial populations.
Collinsella aerofaciens bacterial population
A first purified bacterial population consists of bacteria comprising a 16S rDNA sequence at least about 97% identical to a sequence present in a reference Collinsella aerofaciens OTU.
Clostridiaceae bacterial population
A second purified bacterial population consists of bacteria comprising a 16S rDNA sequence at least about 97% identical to a sequence present in a reference bacterium of the family Clostridiaceae listed in Table 1.
Synergistic pathogen inhibition
The first and second purified bacterial populations form a synergistic combination that is cytotoxic or cytostatic to a pathogenic bacterium and exerts an inhibitory effect on a pathogenic bacterium present in or entering into the gastrointestinal tract of the human subject.
Treatment or prevention of Clostridium difficile infection
The composition is administered to a human subject in need thereof to treat or prevent an occurrence or recurrence of Clostridium difficile infection, such that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
The independent claim centers on administering the specified synergistic bacterial combination to exert an inhibitory effect on pathogenic bacteria in the gastrointestinal tract and treat or prevent Clostridium difficile infection.
Stated Advantages
The bacterial consortia are designed to restore or augment gut microbiota and exert an inhibitory effect on a pathogenic bacterium present in or entering into the gastrointestinal tract.
The selected inhibitory consortia are described as a standardized alternative to fecal transplantation.
The synergistic combination is cytotoxic or cytostatic to a pathogenic bacterium, ensuring that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
The claimed method treats or prevents an occurrence or recurrence of Clostridium difficile infection in a human subject.
A detectable reduction in the number of Clostridium difficile bacteria in or excreted from the gastrointestinal tract occurs within one month after administration.
Documented Applications
Treatment or prevention of an occurrence or recurrence of Clostridium difficile infection in a human subject.
Oral administration or use in a medical-food formulation.
Interested in licensing this patent?